Small cell lung cancer(SCLC)is a highly invasive neuroendocrine carcinoma that is prone to metastasis and progression,with high rates of drug resistance and recurrence.The current treatment options have limited benefits for patient survival.On May 16,2024,the FDA approved the marketing of tarlatamab,providing a new treatment plan for SCLC patients who have previously received first-line or second-line treatment.Clinical studies have shown that this drug is effctive and safe.This article reviews the pharmacological effects,clinical studies,safety,usage and dosage of tarlatamab.
small cell lung cancertarlatamabclinical evaluationsafety
NETL
NSTL
万方数据
